ストックスクリーナーアプリを入手
6.71
0.00%
0.00
プレマーケット:
7.10
0.39
+5.81%
前日終値:
$6.71
開ける：
$6.66
24時間の取引高:
106.13K
Relative Volume:
0.58
時価総額：
$83.10M
収益：
$4.28M
当期純損益:
$-7.28M
株価収益率:
-8.2372
EPS:
-0.8146
ネットキャッシュフロー:
$-6.17M
1週間 パフォーマンス:
-1.32%
1か月 パフォーマンス:
-14.74%
6か月 パフォーマンス:
+143.12%
1年 パフォーマンス:
+165.22%
1日の値動き範囲:
$6.66
$7.005
1週間の範囲:
$6.49
$7.064
52週間の値動き範囲:
$2.1963
$9.33
Neuraxis Inc Stock (NRXS) Company Profile
名前
Neuraxis Inc
セクター
電話
(812) 689-0791
住所
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
6.71 | 84.21M | 4.28M | -7.28M | -6.17M | -0.8146 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuraxis Inc (NRXS) 最新ニュース
NeurAxis Stockholders Approve Directors and Equity Compensation Plans - TipRanks
Neuraxis elects board members and approves plan amendments at annual meeting - Investing.com
NRXS Q1 2026 Earnings: Smaller-than-Expected Loss Bolsters Investor SentimentShare Repurchase Impact - newsline.com
NRXS Q1 2026 Earnings: EPS Beats Estimates Amid Ongoing Development FocusGuidance Accuracy Score - newsline.com
NRXS Q1 2026 Earnings: EPS Beats Estimates but Stock Declines on Broader ConcernsBalance Sheet Strength - newsline.com
NRXS Q1 2026 Earnings: EPS Beat Surprises as Pre-Revenue Biotech Tightens LossesEstimate Revision Count - The Legal Advocate
NRXS Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionForward EPS Estimate - thelegaladvocate.com
Neuraxis Inc. (NRXS) Slides 2.15% as Key Support Level TestedPCR Divergence - The Legal Advocate
NRXS: Record Q1 revenue and expanded coverage drive growth in pediatric and VA neuromodulation markets - TradingView
NRXS Q1 2026 Earnings: EPS Beats Estimates Despite Revenue AbsenceRevenue Warning Signal - The Legal Advocate
Neuraxis Inc. (NRXS) Q1 2026 Earnings: EPS Surpasses Estimates Amid Operational ProgressGAAP Earnings Report - The Legal Advocate
Neuraxis Inc. (NRXS) Holds Near Support After Marginal DeclineMA Cross Alert - Newser
Neuraxis Inc. (NRXS) Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Slips on Pre‑Revenue Concerns - Newser
NeurAxis Earnings Call Highlights Growth and Hurdles - TipRanks
NeurAxis (NRXS) Gains on Reimbursement Updates and Guideline MomentumShare Dilution Risk - The Legal Advocate
Minot Light Capital Fund Drops 2.7 Percent Amid Sector Rotation - HarianBasis.co
NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum - Insider Monkey
Neuraxis (NRXS) Stock Analysis: -5.84% Loss — Key Levels 2026-05-18Stock Idea Hub - Newser
NeurAxis slides 21%, raises $5M via stock - MSN
The surprise hidden in Neuraxis NRXS last earnings report Q4 2025 Earnings Beat EstimatesCrowd Verified Signals - Newser
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y - Yahoo Finance
NeurAxis revenues up 80% to USD 1.6M in Q1 2026 - Medical Buyer
TradingKey - TradingKey
NeurAxis signals burn rate of $1M or less for rest of 2026 while targeting ~ $15M revenue for cash flow breakeven - MSN
Neuraxis Inc (NRXS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Coverage Challenges - Investing.com Canada
Earnings call transcript: Neuraxis Q1 2026 sees record revenue growth - Investing.com
Earnings call transcript: Neuraxis Q1 2026 sees record revenue growth By Investing.com - Investing.com India
Neuraxis Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
NRXS: Q1 2026 revenue up 80% year-over-year, with margin and adoption gains in covered markets - TradingView
NeurAxis, Inc. Reports 80% Revenue Growth in Q1 2026 Driven by CPT Code Assignment and Expanded Product Adoption - Quiver Quantitative
Neuraxis, INC 1Q 2026: Revenue $1.61M, EPS $(0.18) — 10-Q Summary - TradingView
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth - GlobeNewswire
NeurAxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
The surprise hidden in Neuraxis (NRXS) last earnings report | Q4 2025: Earnings Beat EstimatesCommunity Risk Signals - newser.com
Neuraxis | ARS: Annual Report to Security Holders - Moomoo
NeurAxis (NRXS) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
What the smart money sees in Neuraxis (NRXS) that retail does not (Near Lows) 2026-05-08Open Stock Picks - newser.com
Number of shareholders of Neuraxis, Inc. – AMEX:NRXS - TradingView
NRXS Neuraxis Q4 loss narrows more than expected, but shares dip 0.11% despite EPS beat.CFO Commentary - newser.com
The critical factors shaping Neuraxis (NRXS) future (Technical Weakness) 2026-05-08Retail Trader Ideas - newser.com
This Small-Cap Healthcare Stock Is Up 300% in a Year and Is Quickly Gaining a Following - inkl
NeurAxis will post first-quarter results before market open May 12 - Stock Titan
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026 - GlobeNewswire
The Zacks Analyst Blog Highlights Alphabet, Walmart, Micron Technology and NeurAxis - Yahoo Finance
Top stock reports for Alphabet, Walmart & Micron - MSN
Bigger Capital, Michael Bigger report NRXS holdings (NRXS) and warrant limits - Stock Titan
Neuraxis | SCHEDULE 13G/A: Others - Moomoo
Neuraxis (NRXS) director Gil reports stock awards from Series B dividend - Stock Titan
Neuraxis | 4: Statement of changes in beneficial ownership of securities-Director Aharon Gil - Moomoo
Neuraxis Inc (NRXS) 財務データ
収益
当期純利益
現金流量
EPS
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):